769 related articles for article (PubMed ID: 17452316)
1. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation.
Zhang DW; Lagace TA; Garuti R; Zhao Z; McDonald M; Horton JD; Cohen JC; Hobbs HH
J Biol Chem; 2007 Jun; 282(25):18602-18612. PubMed ID: 17452316
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding.
Gu HM; Adijiang A; Mah M; Zhang DW
J Lipid Res; 2013 Dec; 54(12):3345-57. PubMed ID: 24103783
[TBL] [Abstract][Full Text] [Related]
3. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor.
Zhang DW; Garuti R; Tang WJ; Cohen JC; Hobbs HH
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13045-50. PubMed ID: 18753623
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis for LDL receptor recognition by PCSK9.
Kwon HJ; Lagace TA; McNutt MC; Horton JD; Deisenhofer J
Proc Natl Acad Sci U S A; 2008 Feb; 105(6):1820-5. PubMed ID: 18250299
[TBL] [Abstract][Full Text] [Related]
5. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
6. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.
Shan L; Pang L; Zhang R; Murgolo NJ; Lan H; Hedrick JA
Biochem Biophys Res Commun; 2008 Oct; 375(1):69-73. PubMed ID: 18675252
[TBL] [Abstract][Full Text] [Related]
7. Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification.
Tveten K; Holla ØL; Cameron J; Strøm TB; Berge KE; Laerdahl JK; Leren TP
Hum Mol Genet; 2012 Mar; 21(6):1402-9. PubMed ID: 22156580
[TBL] [Abstract][Full Text] [Related]
8. Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function.
DeVay RM; Yamamoto L; Shelton DL; Liang H
PLoS One; 2015; 10(4):e0125127. PubMed ID: 25905719
[TBL] [Abstract][Full Text] [Related]
9. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.
Nassoury N; Blasiole DA; Tebon Oler A; Benjannet S; Hamelin J; Poupon V; McPherson PS; Attie AD; Prat A; Seidah NG
Traffic; 2007 Jun; 8(6):718-32. PubMed ID: 17461796
[TBL] [Abstract][Full Text] [Related]
10. Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.
Kosenko T; Golder M; Leblond G; Weng W; Lagace TA
J Biol Chem; 2013 Mar; 288(12):8279-8288. PubMed ID: 23400816
[TBL] [Abstract][Full Text] [Related]
11. Sorting an LDL receptor with bound PCSK9 to intracellular degradation.
Leren TP
Atherosclerosis; 2014 Nov; 237(1):76-81. PubMed ID: 25222343
[TBL] [Abstract][Full Text] [Related]
12. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
13. Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels.
Mayer G; Poirier S; Seidah NG
J Biol Chem; 2008 Nov; 283(46):31791-801. PubMed ID: 18799458
[TBL] [Abstract][Full Text] [Related]
14. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
[TBL] [Abstract][Full Text] [Related]
15. New hypotheses about the structure-function of proprotein convertase subtilisin/kexin type 9: analysis of the epidermal growth factor-like repeat A docking site using WaterMap.
Pearlstein RA; Hu QY; Zhou J; Yowe D; Levell J; Dale B; Kaushik VK; Daniels D; Hanrahan S; Sherman W; Abel R
Proteins; 2010 Sep; 78(12):2571-86. PubMed ID: 20589640
[TBL] [Abstract][Full Text] [Related]
16. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation.
Fisher TS; Lo Surdo P; Pandit S; Mattu M; Santoro JC; Wisniewski D; Cummings RT; Calzetta A; Cubbon RM; Fischer PA; Tarachandani A; De Francesco R; Wright SD; Sparrow CP; Carfi A; Sitlani A
J Biol Chem; 2007 Jul; 282(28):20502-12. PubMed ID: 17493938
[TBL] [Abstract][Full Text] [Related]
17. Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.
Le QT; Blanchet M; Seidah NG; Labonté P
J Biol Chem; 2015 Sep; 290(38):23385-400. PubMed ID: 26195630
[TBL] [Abstract][Full Text] [Related]
18. A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9.
Holla ØL; Strøm TB; Cameron J; Berge KE; Leren TP
Mol Genet Metab; 2010 Feb; 99(2):149-56. PubMed ID: 19828345
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
20. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
